Retatrutide
Investigational (clinical trials)Research-use peptide · also: ly3437943, triple g
An investigational triple-hormone-receptor agonist (GIP/GLP-1/glucagon) still in clinical trials.
People commonly track it for
Discussed in a weight-and-metabolic context; it is not an available medicine.
Evidence summary
In Phase 3 clinical trials per ClinicalTrials.gov. Not FDA-approved for any use.
Regulation & source status
Investigational only — not FDA-approved and not lawfully compounded; access is limited to registered clinical trials. Products sold to consumers as 'retatrutide' are unverified.
Route considerations
Available only within clinical trials. We don't provide any preparation or technique guidance.
Storage considerations
Anything sold outside a trial is unverified — storage and contents cannot be trusted.
Interaction & context review
Because human data is limited, interactions aren't well characterized. If you track it alongside other items or medications, review the full list with a clinician or pharmacist.
Track this item
You can log this as a custom peptide / medication-context item — record your own source status, route, storage note, and a schedule, and include it in an export for your clinician. StackWise doesn't add a dose.
Track this itemPeptide safety & source review
Sources
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
- ClinicalTrials.gov — retatrutide (Phase 3)
Source reviewed: 2026-07-23.